Trial NCT01621477

View at ClinicalTrials.gov 
Org. Study IDs: HAP3R
Secondary IDs: NCI-2012-00554

Last trial update was posted on 2017-02-20

MeSH Interventions

Antilymphocyte Serum Busulfan Clofarabine Cyclophosphamide Cytarabine Mycophenolic Acid Plerixafor Tacrolimus Thymoglobulin

MeSH Conditions

Hematologic Neoplasms Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Myelomonocytic, Juvenile Myelodysplastic Syndromes Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Sarcoma, Myeloid

Other Conditions

Acute Lymphoblastic Leukemia Acute Myelocytic Leukemia Chronic Myelocytic Leukemia Hodgkin or Non-Hodgkin Lymphoma Juvenile Myelomonocytic Leukemia Myelodysplastic Syndrome

Stopping Reasons

Study was terminated in August 2016 due to replacement by a new study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID